The highest score in the Prescription Justice Congressional Report Card on Drug Prices – 100 – goes to Representative Jan Schakowsky (D-IL), with a grade of A+. The only other A+ in the House goes to Rep. Perter Welch (D-VT), who landed a score of 99.5.
Prescription Justice is pleased to announce that Isaiah Cochran, MD has been appointed to the Prescription Justice Board of Directors.
Dr. Cochran is the immediate past president and chair of the board of trustees for the American Medical Student Association (AMSA). He served as a key organizational spokesperson for AMSA and as an active promoter of the organization's educational programming, advocacy pursuits, and membership recruitment and engagement efforts.
Today, President Trump announced four executive orders with the stated intent of substantially lowering drug prices. Briefly, the administration’s bluster on drug prices over the past three years has been far louder than any actions taken to actually do something about it. Better late than never.
The orders call for and include: 1) Lower prices on EpiPens and insulin, 2) Allowing personal drug importation, 3) Ending profit-taking by pharmacy benefit manager middlemen, and 4) “most favored nation” drug price negotiation in Medicare, meaning Medicare would get the lowest price on drugs of any country.
The Prescription Justice Board of Directors recently approved a statement regarding Covid-19. The Board recognizes that Covid-19 infuses the crisis of high drug prices with greater life-and-death urgency.
Prescription Justice is proud to announce that a statement prepared by PJ President Gabriel Levitt for the U.S. House Ways and Means Committee on “Investing In The U.S. Health System By Lowering Drug Prices, Reducing, Out-of-Pocket Costs and Improving the Medicare Benefit” is now part of the official congressional record.